Approximately two-thirds of patients with Crohn's disease who initially responded to tumor necrosis factor (TNF) inhibitors lost response by the third year of treatment, a population-based ...

Continuing anti-tumor necrosis factor (anti-TNF) therapy after 24 weeks of pregnancy is associated with a lower likelihood of relapse of inflammatory bowel disease (IBD) in pregnant women and fewer ...

LAS VEGAS -- Children and teens with Crohn's disease who received early tumor necrosis antagonist (anti-TNF) treatment had a lower risk of developing perianal fistulizing complications (PFCs) than ...

One of the key aspects of the use of TNF inhibitors is their overall risk/benefit ratio. While almost all clinicians are quite familiar with the potentially very positive clinical responses achieved ...

Please provide your email address to receive an email when new articles are posted on . At baseline, 26.6% of children with Crohn’s had a weight disturbance, 27.7% had a height disturbance and 19.7% ...

Anti-TNF-α biosimilars showed a 91% drug survival rate at 12 months, with no significant differences between infliximab, etanercept, and adalimumab. Long-term effectiveness and safety of anti-TNF-α ...

Please provide your email address to receive an email when new articles are posted on . Low anti-TNF drug concentrations at week 14 predicted loss of response at years 2 and 3. Optimal drug ...

Background Patients with psoriasis (PsO) are at increased risk of developing psoriatic arthritis (PsA). Emerging evidence ...

Early treatment of pediatric Crohn's disease with anti-tumor necrosis factor medications can substantially reduce the risk of perianal fistulas, a particularly debilitating complication of Crohn's ...